Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.

[1]  Sunghoon Kim,et al.  In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. , 2003, The Journal of antimicrobial chemotherapy.

[2]  Yun-Jeong Choi,et al.  In Vitro and In Vivo Antibacterial Activities of DW286, a New Fluoronaphthyridone Antibiotic , 2002, Antimicrobial Agents and Chemotherapy.

[3]  D. Hooper,et al.  Bactericidal Activities of BMS-284756, a Novel Des-F(6)-Quinolone, against Staphylococcus aureus Strains with Topoisomerase Mutations , 2002, Antimicrobial Agents and Chemotherapy.

[4]  L. Discotto,et al.  Staphylococcus aureus Mutants Selected by BMS-284756 , 2001, Antimicrobial Agents and Chemotherapy.

[5]  D. Hooper,et al.  Mechanisms of action of antimicrobials: focus on fluoroquinolones. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Inoue,et al.  Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus , 1996, Antimicrobial agents and chemotherapy.

[7]  H. Ito,et al.  Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus , 1994, Antimicrobial Agents and Chemotherapy.

[8]  Henry D. Isenberg,et al.  Clinical Microbiology Procedures Handbook , 2004 .

[9]  M J Ferraro.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[10]  T. Nukiwa,et al.  Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. , 1998, The Journal of antimicrobial chemotherapy.